Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- Stigma, Gender Violence Placing Women In Caribbean At Increased Risk Of HIV
- Many Americans Support Increased Domestic Funding To Address HIV/AIDS, Report Says
- Induction Of Antibodies That Block HIV Prevented By Biological Catch-22
- Iran's Health Ministry Releases Figures On HIV/AIDS Cases
- Needle Exchange Programs Could Save Texas 'Millions Of Dollars,' Opinion Piece Says
- Senate Confirms Goosby As U.S. Global AIDS Coordinator
- IRIN Examines HIV/AIDS Advocates' Reaction To U.N. Agency For Women
- Federal Officials To Study New Strategy To Boost HIV Testing, Treatment
- Boston Arm Of Multi-City Study To Focus On Sexual Health, HIV Risk Among Black Gay, Bisexual Men
- Proteomics Technology To Focus On Neurological Complications Of HIV
Prescription AIDS Drugs
Contact Us
Leading Vaccine Discovery Expert Joins The International AIDS Vaccine Initiative (IAVI)
May 07th, 2009
Dr. C. Richter (Rick) King, former Senior Vice President of Research at GenVec, Inc., has joined the International AIDS Vaccine Initiative (IAVI) as Vice President of Vaccine Discovery. In his new position, Dr. King will play a vital role in leading and managing IAVI’s global vaccine discovery initiatives in support of IAVI’s mission: to ensure the development of a safe, effective, accessible and preventive AIDS vaccine.
A biochemist by training, Dr. King received his PhD from Johns Hopkins University and his BS from the University of St. Andrews. He has worked in government, academia and in industry, and is well known for his innovative discoveries in cancer biology. He played an integral role in the discovery of a molecular abnormality that occurs with certain breast cancers. This breakthrough led to the development of better diagnostic tools and targeted treatments for breast cancer.
For the past decade, Dr. King’s role at GenVec has been to translate scientific discovery into experimental treatments and preventative agents for unmet medical needs. He has led the company’s efforts in the identification, selection and advancement of products for cancer, ocular and infectious disease applications. These include a therapeutic for pancreatic cancer currently in Phase III clinical trial, a therapeutic for age-related macular degeneration in Phase Ib trials, and viral vector based vaccines for prevention of malaria and HIV currently in Phase I/II trials. Dr. King has been the author and recipient of many peer reviewed grants, is an inventor on 12 issued patents, and has published more than 70 peer-reviewed publications.
“We are excited to have a scientist of Dr. King’s caliber join our research and development team,” said Dr. Wayne Koff, Senior Vice President, Research and Development at IAVI. “Dr. King’s experience will prove indispensable in leading our global efforts to design and prioritize novel AIDS vaccine strategies.”
“One of the biggest challenges of any vaccine discovery effort is determining the vaccine candidates that are worth pursuing and those that are not,” said King. “My job at IAVI will be to work together with IAVI scientists and partners to do just that. There are several innovative vaccine candidates currently in pre-clinical development at IAVI, and I hope to help bring the most promising ones into human testing over the next few years.”
As evidence has grown that creating an effective AIDS vaccine requires more applied research aimed at solving the key scientific problems impeding AIDS vaccine development, IAVI has significantly expanded its vaccine discovery portfolio. Dr. King will oversee a comprehensive AIDS vaccine discovery program that now includes:
- an Innovation Fund focused on supporting novel vaccine discovery platforms from industry
- a Human Immunology Laboratory in London linked to partnered Clinical Research Centers in the developing world focused on translating clues from HIV infection to vaccine discovery
- an AIDS Vaccine Design and Development Laboratory in New York focused on the design and prioritization of novel vaccine platforms and
- the IAVI Neutralizing Antibody Center at the Scripps Research Institute in La Jolla, California focused on solving the problem of how to create a vaccine that elicits antibodies capable of neutralizing HIV.
To date, there have only been two AIDS vaccine candidates that have been fully tested in human efficacy trials; both proved ineffective at preventing or controlling HIV infection. With 2.5 million people infected with HIV each year, there remains an urgent need for a safe and effective AIDS vaccine.
Source
International AIDS Vaccine Initiative
Related posts:
- Two Leading Research Institutions Partner To Accelerate The Development Of An AIDS Vaccine Candidate The International AIDS Vaccine Initiative (IAVI) announced that it has...
- New Advances On The Long Road To The Development Of An AIDS Vaccine AIDS Vaccine Day, May 18, marks the occasion in 1997...
- African Institutions Lead International Consortia In $49 Million Initiative More than fifty institutions from eighteen African countries - from...
- Discovery Of Two Antibodies Could Move AIDS Vaccine Development Forward News Category Menu HIV / AIDS >Categories A-B Abortion...
- Potential Achilles Heel On The Virus For AIDS Vaccine Discovered Researchers at and associated with the International AIDS Vaccine Initiative...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.